NeuroPhage adds $9M in venture money; EntreMed looks to China; AMAG touts Feraheme data;

@FierceBiotech: Navy maneuvers to bombard dengue fever in vaccine study. Story | Follow @FierceBiotech

@JohnCFierce: J&J wows analysts with early success of Zytiga Ph3 for prostate cancer. News | Follow @JohnCFierce

@RyanMFierce: Props to Bellicum Pharma, not only for the new $20M B round, but also for the transparent explanation of the deal. Release | Follow @RyanMFierce

> Cambridge, MA-based NeuroPhage Pharmaceuticals has added $9 million in venture cash from a Series B-1 round. Merieux Developpement and Shire contributed money to the round, which will fund its work on neurodegenerative diseases. Release

> Rockville, MD-based Entremed says that it is opening up a China office to help facilitate development efforts and improve the odds of an eventual approval of its lead therapy. Release

> AMAG Pharmaceuticals said its anemia drug Feraheme proved non-inferior to a standard therapy in a late-stage study. Report

> The U.K.'s Circassia says its ragweed allergy therapy reaped positive results in a Phase II clinical trial. Release

> The Mid-Atlantic Bio conference announced that the North Carolina Biotechnology Center has joined the Virginia Biotechnology Association, Tech Council of Maryland, and Mid-Atlantic Venture Association as a 2012 strategic partner. Release

Pharma News

@FiercePharma: More OTC drugs? FDA may allow more meds to go non-prescription. Consumer-use studies still required. Story | Follow @FiercePharma

> Health plans sue Big Pharma over co-pay coupons. Story

CRO News

> Biosimilars growth draws contract labs into the fray. More

> Survey: Look for strong growth in R&D outsourcing, shift to India and China. Report

> Frustrated Pfizer seeks Euro recruitment contractor for 'virtual' trial. Article

> Survey zeroes in on CRO frustrations. Item

Vaccines News

> Is Agenus on GSK's shopping list? More

> Inovio vaccine targets head and neck HPV subtypes. Report

> Gradalis' personalized cancer vaccine has FANGs. Story

> Microneedles trigger better responses to flu vaccine. Article

Manufacturing News

> AMRI names quality control director for troubled plant, following lead of J&J, Novartis, others. Item

> Almac builds on U.S. expansion with $10M pharmaceutical packaging plant. Article

> FDA cites company making 'baby switching' protection kit. News

And Finally… Investigators at the University of Texas at Austin have developed a 3-D paper sensor that may be able to test for diseases such as malaria and HIV for less than 10 cents a pop. Release

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.